Medical Information

The use of Lifnua tablets requires special attention to liver function monitoring, photosensitive reaction prevention, and drug interaction management. The following details the precautions from these three aspects to ensure medication safety and effectiveness.

1. Liver function monitoring

(1) Monitoring frequency

Before treatment, ALT, AST, and bilirubin levels need to be checked. Monitor once a month for the first 3 months and once every 3 months thereafter. Check at any time when abnormal symptoms occur.

(2) Dose adjustment

If ALT/AST increases by more than 3 times ULN and bilirubin increases by more than 2 times ULN, the medication should be stopped immediately. Mild to moderate abnormalities can be reduced by 50% and monitoring can be strengthened.

2. Prevention of photosensitive reactions

(1) Protective measures

During the treatment period, it is necessary to avoid direct sunlight, use SPF50+sunscreen when going out, wear protective clothing, and reduce exposure to sunlight.

(2) Symptom management

When severe rash or photosensitivity occurs, medication should be reduced or suspended, and antihistamines or corticosteroids should be used for symptomatic treatment if necessary.

3 drug interactions

(1) CYP enzyme influence

Avoiding combination with potent CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin) may significantly alter blood drug concentrations.

(2) Special drugs

The combination with warfarin requires an increase in INR monitoring frequency, while the combination with P-glycoprotein substrate may require adjustment of the latter dosage.